T1	Participants 733 741	patients
T2	Participants 1656 1674	enzalutamide group
T3	Participants 1707 1721	placebo group.
T4	Participants 2182 2190	patients
T5	Participants 2198 2216	enzalutamide group
T6	Participants 2229 2242	placebo group
T7	Participants 2746 2764	enzalutamide group
T8	Participants 2777 2790	placebo group
T9	Participants 2937 2947	patients i
T10	Participants 3009 3022	placebo group
T11	Participants 3132 3150	enzalutamide group
T12	Participants 3242 3255	placebo group
T13	Participants 3365 3386	placebo, enzalutamide
